Cel Sci Corporation (CVM)

[lightrock]

That's interesting...

Roche found about 12% of those who received Actemra plus standard of care needed breathing support or died through four weeks, compared to roughly 19% of those who go standard treatment alone, meeting the trial's goal.

But the results didn't show a statistically significant benefit on any of the secondary measures studied, such as the time needed for patients to recover and leave the hospital. Most notably, Roche said about 10% of Actemra-treated patients had died by day 28, versus roughly 9% of placebo-treated patients.

In other news, you can find where vaso-dilation is responsible for too much blood flowing too fast through the lungs to exchange gas.

So if you can mitigate that issue, you can keep blood oxygen levels up and reduce the need for the machinery.

It doesn't necessarily have to do anything directly to the virus to treat that symptom.